What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?

Archives of Pediatrics and Adolescent Medicine

Volumn 165, Issue 9, 2011, Pages 867-868

  Saiman, Lisa ^a,b   Cohen, Mitchell B ^c,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CIPROFLOXACIN; PLACEBO; TOBRAMYCIN;

ANTIMICROBIAL ACTIVITY; BREATHING EXERCISE; CHILD; CHILDHOOD DISEASE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; EDITORIAL; HUMAN; INFANT; INFANT DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SCHOOL CHILD; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 80052498518     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2011.133     Document Type: Editorial

References (8)

1. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., et al Early Pseudomonas Infection Control Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165(9):847-856.
2. Gold R., Carpenter S., Heurter H., Corey M., Levison H. Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr. 1987;111(6, pt 1):907-913. (Pubitemid 18019173)
3. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.AmRev Respir Dis. 1990;141(4, pt 1):914-921. (Pubitemid 20157719)
4. Ramsey B.W., Pepe M.S., Quan J.M., et al Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340(1):23-30. (Pubitemid 29024680)
5. Ratjen F., Munck A., Kho P., Angyalosi G.; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax. 2010;65(4):286-291.
6. Cystic Fibrosis Foundation Patient Registry 2009 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
7. Zhou J., Garber E., Desai M., Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Microbiol. 2006;44(4):1547-1549.
8. Waters V., Yau Y., Prasad S., et al. Stenotrophomonas maltophilia in cystic fibrosis: Serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011;183(5):635-640.